Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Oasmia Pharmaceutical Announces Licensing Agreement With Orion Corporation Regarding New Innovative Ovarian Cancer Drug Candidate, Paclical(R)

Abstract:
Oasmia Pharmaceutical, Sweden and Orion Corporation, Finland, have entered a license and distribution agreement for marketing and sales of the human cancer drug Paclical(R) (micellar paclitaxel) in the Nordic region, encompassing Sweden, Denmark, Norway, Finland and Iceland. The product is currently entering Phase III development by Oasmia, with ovarian cancer as the target indication.

Oasmia Pharmaceutical Announces Licensing Agreement With Orion Corporation Regarding New Innovative Ovarian Cancer Drug Candidate, Paclical(R)

UPPSALA, Sweden | Posted on November 27th, 2007

Orion receives the exclusive rights in the Nordic region to distribute and sell the product. Orion will also have first right of refusal for one more cancer drug candidate in the Oasmia product portfolio in this region. According to the agreement, Oasmia will receive payments of EUR 4 million, partly up front and partly subject to a successful development and regulatory process for Paclical(R), as well as royalties from the sales.

Oasmia will be responsible for the clinical development, registration and production of Paclical(R). Paclical(R) is currently entering into clinical phase III and further clinical studies in ovarian cancer are planned for the first quarter of 2008. Other indications will follow during the same year. Orion Corporation will be responsible for the distribution and sales in the Nordic region after registration.

- "We are very pleased to announce our agreement with Orion, as the first in a number of upcoming agreements for the world-wide distribution of Paclical(R). Orion, with it's strong presence and long tradition in the Nordic region, is an ideal partner to reach cancer patients with our product in this region, which represents approximately five per cent of the world market for Paclical(R). The market for taxanes currently exceeds EUR 61 million yearly in the region. We regard this agreement as the first step in a broader co-operation between Orion and Oasmia," says Julian Aleksov, CEO of Oasmia.

- "Orion is pleased to work towards bringing new treatments for cancer patients. This product will offer an improved way to treat ovarian cancer and Oasmia's work in this field will hopefully materialise in other innovative treatments as well. For Orion's Urology and Oncology business area this is an important product," says Timo Lappalainen, Senior Vice President of Proprietary Products division at Orion.

About Paclical(R)

Paclical(R) is a novel water soluble, solvent-free nano particle formulation based on the well known cytotoxic agent paclitaxel. The unique properties of Paclical(R) are based on Oasmia's nanotechnologically produced excipient and micellar model XR-17 which is protected by international patents. The novel platform makes paclitaxel hydrophilic, makes premedication unnecessary, shortens the infusion time and facilitates the infusion.

####

About Oasmia Pharmaceutical
Oasmia Pharmaceutical AB develops next generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia co-operates with leading universities and other biotech companies to discover and optimize substances with a favourable safety profile and better efficacy. The company was founded in 1998 and is based in Uppsala, Sweden. For more information, please visit: http://www.oasmia.com

About Orion

Orion is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. In 2006, Orion generated sales of EUR 641.1 million and invested EUR 84.1 million in research and development. Orion Corporate headquarters are situated in Espoo, Finland and the company has approximately 3,060 employees. For more information, please visit: http://www.orion.fi/english/

More information is available at http://www.ngm.se or http://www.oasmia.com

Oasmia Pharmaceutical AB is a pharmaceutical company that specialises in the treatment of severe diseases based on the latest concepts in bio-organic chemistry. Our vision is to improve the treatment of serious diseases. Primarily, this development is in oncology but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is listed on NGM Eguity.

For more information, please click here

Contacts:
Maria Lundén
+46 18 56 96 92

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE